Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

As Losses Mount, There Are Way Better Buys Than Lemonade Stock

By Mark R. Hake, CFA

Stay away from Lemonade stock as it has no plans to get profitable. Lemonade stock is way too expensive compared with Assurant for it to be considered a bargain investment.

AMD Can’t Sustain Its Stratospheric Valuation

By Mark R. Hake, CFA

Advanced Micro Devices can't sustain its stratospheric valuation. AMD stock at 69 times earnings is overvalued, especially if Intel gets its 7-nanometer chip production back up.

Alphabet Stock is a Play on Economic Recovery as Advertising Picks Up

By Mark R. Hake, CFA

Alphabet stock is a play on economic recovery as advertising picks up. GOOGL is worth at least 28% more based on its expected FCF and diversified revenue growth.

Apple Still Looks Expensive But iPhone Launch Could Push It Higher

By Mark R. Hake, CFA

AAPL stock looks somewhat expensive here but Apple's new 5G iPhone launch could be a catalyst.Keep a close eye on it.

The Kensington Capital Merger With QuantumScape Will Be a Winner

By Mark R. Hake, CFA

Kensington Capital stock could push at least 50% higher after the merger if QuantumScape's lithium metal technology pans out.

Nikola’s Troubles With Short Sellers Raise Questions About Its Value

By Mark R. Hake, CFA

NKLA stock could lose more value depending on the official terms of its agreement with GM. It may be wisest to wait.

Novavax Stock Has a Clear Path to Over $200

By Mark R. Hake, CFA

Novavax is likely to recover with its vaccine results. If successful, I think its vaccine will make NVAX stock worth at least $229.

It May Take Some Time but Delta Air Lines Will Turn Around

By Mark R. Hake, CFA

It may take some time but Delta Air Lines will turn around. DAL stock could easily double over the next two and a half years or at least 32% annually as its recovery takes hold.

Why You Should Stay Away From Genius Brands Stock

By Mark R. Hake, CFA

Stay away from Genius Brands stock even though it has cratered. GNUS stock is worth at best only 46 cents per share, implying an expected drop of 56% from here.

5 In-The-Money Warrants of SPAC Stocks With Merger Agreements

By Mark R. Hake, CFA

These in-the-money warrants of SPAC stocks with merger agreements offer significant leverage over their related securities.

Load More